Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 4/20 | 0.51 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.38 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.38 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.38 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.38 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | USP10 | Q14694 | 1/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.39 |
| ▸ | USP13 | Q92995 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL441924 | 0.99 | EGFR (0.52) | EGFRUTS2RLRRK2ADORA2AADORA1 | |
| Hydrochloric Acid SCHEMBL436303 | 0.83 | UTS2R (0.53) | EGFRUTS2RLRRK2KDM4EALDH1A1 | |
| SCHEMBL439027 | 0.81 | UTS2R (0.54) | EGFRUTS2RLRRK2KDM4EALDH1A1 | |
| SCHEMBL3777297 | 0.79 | MAP2K4 (0.50) | EGFRUTS2RLRRK2MAP2K4THRB | |
| Hydrochloric Acid SCHEMBL436264 | 0.73 | KDM4E (0.45) | EGFRLRRK2THRBKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL2318211 | 0.73 | UTS2R (0.40) | EGFRUTS2RLRRK2MAP2K4THRB | |
| SCHEMBL437183 | 0.72 | KDM4E (0.46) | LRRK2THRBKDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL437236 | 0.72 | UTS2R (0.41) | EGFRUTS2RLRRK2THRBKDM4E | |
| Hydrochloric Acid SCHEMBL438326 | 0.72 | MAPT (0.43) | EGFRLRRK2THRBKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL439779 | 0.72 | LRRK2 (0.41) | UTS2RLRRK2THRBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513277-B2 | Pyrrolo[3,2-C] pyridine derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2013-08-20 | — | — | US | claimed |
| US-20120065224-A1 | PYRROLO[3,2-C) PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2012-03-15 | — | — | US | claimed |
| EP-1784402-B1 | PYRROLO[3,2-c]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORP (KR) | 2011-08-03 | — | — | EP | claimed |
| CN-101018788-B | Pyrrolo[3,2-c]pyridine derivatives and processes for the preparation thereof | YUHAN CORP | 2010-08-25 | — | — | CN | claimed |
| US-20090005409-A1 | Pyrrolo[3,2-C] Pyrdine Derivatives and Processes for the Preparation Thereof | YUHAN CORPORATION (KR) | 2009-01-01 | — | — | US | claimed |
| CN-101018788-A | Pyrrolo[3,2-c]pyridine derivatives and processes for the preparation thereof | YUHAN CORP (KR) | 2007-08-15 | — | — | CN | claimed |
| EP-1784402-A1 | PYRROLO[3,2-c]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Yuhan Corporation (KR) | 2007-05-16 | — | — | EP | claimed |
| WO-2006025714-A1 | PYRROLO[3,2-c]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2006-03-09 | — | — | WO | claimed |
| US-8513277-B2 | Pyrrolo[3,2-C] pyridine derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2013-08-20 | — | — | US | disclosed |
| US-8148529-B2 | Pyrrolo[3,2-C] pyridine derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2012-04-03 | — | — | US | disclosed |
| US-20120065224-A1 | PYRROLO[3,2-C) PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2012-03-15 | — | — | US | disclosed |
| EP-1784402-B1 | PYRROLO[3,2-c]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORP (KR) | 2011-08-03 | — | — | EP | disclosed |
| CN-101018788-B | Pyrrolo[3,2-c]pyridine derivatives and processes for the preparation thereof | YUHAN CORP | 2010-08-25 | — | — | CN | disclosed |
| US-20090005409-A1 | Pyrrolo[3,2-C] Pyrdine Derivatives and Processes for the Preparation Thereof | YUHAN CORPORATION (KR) | 2009-01-01 | — | — | US | disclosed |
| CN-101018788-A | Pyrrolo[3,2-c]pyridine derivatives and processes for the preparation thereof | YUHAN CORP (KR) | 2007-08-15 | — | — | CN | disclosed |
| EP-1784402-A1 | PYRROLO[3,2-c]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Yuhan Corporation (KR) | 2007-05-16 | — | — | EP | disclosed |
| WO-2007001139-A1 | A COMPOSITION FOR TREATING OR PREVENTING A CANCER COMPRISING PYRROLOPYRIDINE DERIVATIVES | YUHAN CORPORATION (KR) | 2007-01-04 | — | — | WO | disclosed |
| WO-2006025714-A1 | PYRROLO[3,2-c]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005409-A1 | Pyrrolo[3,2-C] Pyrdine Derivatives and Processes for the Preparation Thereof | ATP6AP1, PPOX, PGA5 | EGFR 4570/4885PTGS2 122/4885ERBB2 3330/4885 |
| US-20120065224-A1 | PYRROLO[3,2-C) PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | PGA5, ATP6AP1, HPD | EGFR 4192/4885PTGS2 159/4885ERBB2 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.